TearSolutions: Naturally Treating Dry Eye (225)
Tear Solutions

TearSolutions’ lead product, called Lacripep, delivers what no other approved or pipeline drug has been able to: rapid healing of the ocular surface and relief of dry eye symptoms with a best-in-class safety and comfort profile. This was all proven in their first-in-human clinical trial which has led to formal written FDA alignment on our clinical and regulatory path to an unrestricted general Dry Eye indication (which is the same path a dry eye drug called Xiidra took, which sold to Novartis for $5.3B). 

The company is raising capital to get Lacripep back into the clinic for the first of two Phase III trials.


Apple
Spotify

Facebook
Twitter
LinkedIn

Recent Posts

Is The Venture Capital Party Over?

Mark Twain famously said “The reports of my death are greatly exaggerated.” Such is the…

Ai Juggernaut Palantir Enters Healthcare

Palantir is not exactly a household name, but the Peter Thiel founded company now based…

PE Perspectives

Triple Tree and Bain & Co are two very sharp private equity firms and when…